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Bronchial epithelial repairCysticﬁbrosis (CF) airway epithelium is constantly subjected to injury events due to chronic infection and inﬂam-
mation. Moreover, abnormalities in CF airway epithelium repair have been described and contribute to the lung
function decline seen in CF patients. In the last past years, it has been proposed that anoctamin 1 (ANO1), a Ca2+-
activated Cl− channel, might offset the CFTR deﬁciency but this protein has not been characterized in CF airways.
Interestingly, recent evidence indicates a role for ANO1 in cell proliferation and tumor growth. Our aims were to
study non-CF and CF bronchial epithelial repair and to determine whether ANO1 is involved in airway epithelial
repair. Here, we showed, with human bronchial epithelial cell lines and primary cells, that both cell proliferation
and migration during epithelial repair are delayed in CF compared to non-CF cells. We then demonstrated that
ANO1 Cl− channel activity was signiﬁcantly decreased in CF versus non-CF cells. To explain this decreased Cl−
channel activity in CF context, we compared ANO1 expression in non-CF vs. CF bronchial epithelial cell lines
and primary cells, in lung explants from wild-type vs. F508del mice and non-CF vs. CF patients. In all these
models, ANO1 expression was markedly lower in CF compared to non-CF. Finally, we established that ANO1 in-
hibition or overexpression was associated respectively with decreases and increases in cell proliferation andmi-
gration. In summary, our study demonstrates involvement of ANO1 decreased activity and expression in
abnormal CF airway epithelial repair and suggests that ANO1 correction may improve this process.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive disease that is due to
mutations in the cystic ﬁbrosis transmembrane conductance regulator
(CFTR) gene encoding an essential cAMP-dependent chloride (Cl−)
channel. Defective CFTR function in the airway epithelium leads to
lung alterations, the main cause of morbidity and mortality of CF
patients.
In CF airway epithelial cells, CFTR impairment results in decreased Cl−
secretion and increased sodium (Na+) inﬂux, leading to an increase in
water absorption that translates into greater viscidity of the airwayvated chloride channel; CF, cys-
ne 508 deletion; RTCA, real time
A, wheat germ agglutinin
U938, Bât. Kourilsky 5ème Étage,
6 23.
ights reserved.surface liquid. In advanced CF, defective ciliary clearance and mucus
hypersecretion cause airway obstruction and produce a favorable envi-
ronment to chronic infection and inﬂammation, resulting in epithelial in-
jury and lung function impairments [1]. In addition, abnormalities in
epithelial injury repair in CF airways have been described [2] and induce
characteristic epithelial remodeling [3]. Several studies have established
involvement of interleukin-8, somemetalloproteinases, and CFTR Cl− ac-
tivity in the epithelial repair process, but the underlying mechanisms re-
main unclear [2,4,5].
Chloride ion movements across the cell membrane are tightly regu-
lated by Cl− channels and transporters, which remain poorly character-
ized in the lungs, the only exception being the CFTR channel. CFTR is the
main gateway for Cl− secretion in the human airway epithelium. How-
ever, alternative Cl− conductance associated with channels called
calcium-activated chloride channels (CaCCs) has been identiﬁed in sev-
eral cell types, including those of secretory epithelia [6,7]. Different au-
thors have compared CaCC activities in human nasal cells and have
observed an increased in CF compared to non-CF group [8–11]. For
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Fig. 1.Cell proliferation andmigration of non-CF and CF bronchial epithelial cell lines in basal conditions. A)Original traces of non-CF and CF cell line proliferationmonitored for 48 h under
basal conditions using real time cell analysis (n = 8, p b 0.001). B) Quantiﬁcation of cell proliferationwithin 48 h performedwith area-under-the-curve (AUC) values normalized to non-
CF cells. C) Representative photographs taken every 6 h during 12 h of wound closure of non-CF and CF cell lines under basal conditions. D)Wound closure kinetics of non-CF and CF cell
lines under basal conditions showed in C.
2341M. Rufﬁn et al. / Biochimica et Biophysica Acta 1832 (2013) 2340–2351this reason it has been proposed that CaCCsmight compensate for CFTR
function impairment in CF patients [11] but the molecular identity of
CaCCs remained unknown for many years. CaCCs are activated by
purinergic signaling through the binding of ATP/UTP to P2Y2 receptor
that induces an increase of intracellular Ca2+ concentration. Based on
this mechanism, a P2Y2 agonist (denufosol tetrasodium) has been de-
veloped and tested in a clinical trial for CF patients. Despite the pos-
itive effects on lung function that have been observed in phase II of
the clinical trial, phase III failed to show a signiﬁcant difference in
lung function of patients treated with denufosol or placebo [12,13].
This study outcome might be due to the short half-life and duration
of action of the molecule [14]. Design of speciﬁc CaCC activators
could improve stimulation; therefore CaCC molecular identiﬁcation
was necessary.
In 2008, three research teams identiﬁed one potential CaCC candi-
date called ANO1 (anoctamin 1) or TMEM16a (transmembrane protein
16a) [15–17]. This protein exhibits all the functional characteristics of
CaCCs, especially regarding the anion permeability sequence and Ca2+
dependence. ANO1 is a transmembrane protein expressed in secretory
epithelia including the airway surface epithelium [18–20]. Mice lacking
ANO1 exhibit decreased Ca2+-activated Cl− secretion and impaired
mucociliary clearance, indicating a substantial physiological role for
ANO1 in the airways [21,22]. Moreover, ANO1 is involved inmucin pro-
duction [23], HCO3−permeability [24] and cytokine secretion [25]. Takentogether, these results indicate that ANO1 is a CaCC andmay be capable
to restore Cl− efﬂux and other important functions dysregulated in CF
airways and could be in a relationship with CFTR protein [26].
Furthermore, ANO1, which is located on the ampliﬁed region 11q13,
is overexpressed in many cancer cells [27–29]. Thus, two different
groups showed that ANO1 inhibition decreased the proliferation of a
human pancreatic cancer cell line [30] and suppressed the growth and
invasiveness of human prostate cancer cells [31]. Moreover, a recent
study showed that ANO1 is a marker of poor prognosis in head and
neck squamous cell carcinoma and implies cell migration [32]. The
exact mechanism by which ANO1 modulates proliferation and migra-
tion of cancer cells is still unknown but Duvvuri and colleagues have re-
cently reported that ANO1 might inﬂuence cell proliferation by
activating the RAS–RAF–MEK–ERK1/2 pathway [33]. These data sug-
gesting the involvement of ANO1 in cell proliferation and migration
led us to hypothesize that ANO1might be involved in airway epithelium
repair.
Here, our main objectives were to study non-CF and CF airway
epithelial repair and to assess ANO1 involvement in this process. We
evaluated epithelial repair using proliferation and wound healing ex-
periments in non-CF versus CF bronchial epithelial cells. We then com-
pared ANO1 activity and expression between many non-CF and CF
airway epithelialmodels. To assess the potential role for ANO1 in airway
epithelial repair we tested the effect of ANO1 inhibition on proliferation
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Fig. 2. Cell proliferation and migration of non-CF and CF primary bronchial epithelial cells in basal conditions. A) Original traces of cell proliferation of non-CF and CF primary cells mon-
itored for 48 h under basal conditions using real time cell analysis. B) Quantiﬁcation of primary non-CF (n = 5) and CF (n = 4) cell proliferationwithin 48 h performedwith area-under-
the-curve (AUC) values normalized to non-CF cells (p b 0.001). C) Representative photographs taken every 2 h during 6 h of wound closure of primary non-CF and CF cells under basal
conditions. D) Migration rates during repair of primary CF (n = 4) compared to non-CF (n = 6) bronchial epithelial cells (p b 0.05).
2342 M. Rufﬁn et al. / Biochimica et Biophysica Acta 1832 (2013) 2340–2351and wound healing. Finally, we investigated the effect of ANO1 overex-
pression on CF bronchial epithelial repair.
2. Materials and methods
2.1. Models
Human bronchial epithelial cell lines 16HBE14o− (non-CF) and
CFBE41o− (CF, F508del/F508del) were provided by Dr. D.C. Gruenert
(San Francisco, CA, USA) and cultured as previously described [34]. Sim-
ilar passage numbers have been used for each cell type.
Primary human bronchial epithelial cells (hAECB) and fully differen-
tiated human bronchial air–liquid-interface cultures (MucilAir™), iso-
lated from bronchial biopsies from non-CF (no pathology reported)
and CF (F508del/F508del) patients, were purchased from EpithelixSARL (Geneva, Switzerland) and cultured according to the provider's
recommendations.
Animal model studies were performed on Cftrtm1Eur adult mice ho-
mozygous for the F508del mutation and their wild-type littermates as
previously described [35]. All animal procedures were performed in ac-
cordance with our institution's guidelines on the care and use of labora-
tory animals.
Human lung explants were collected and processed in compliance
with the current French public health legislation (articles L.1235-2
and L.1245-2, code de la santé publique, www.legifrance.gouv.fr).
Each participating institution informed the patients and made sure
that they were not opposed to the use of surgical samples, removed
during a medical act, for research purpose. Samples and cell cultures
were discarded after use. Lung fragments were obtained from 7 non-
CF patients who underwent surgery (48 ± 26 years) and from 7 CF
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Fig. 3.Chloride channel activity in non-CF andCF bronchial epithelial cells. A) Representative and original traces (left) and quantiﬁcation (right) of CFTR Cl− efﬂuxmeasured in non-CF and
CF cells under basal conditions (n = 5, p b 0.01). B) Representative and original traces (left) and quantiﬁcation (right) of CFTR Cl− efﬂuxmeasured in non-CF cells transfectedwith ANO1
siRNA or treated for 48 h with CFTR(inh)-172 (n = 5, scrambled vs. ANO1 siRNA: p = ns, control vs. CFTR(inh)-172: p b 0.01). C) Representative and original traces (left) and quantiﬁ-
cation (right) of ANO1Cl− efﬂuxmeasured in non-CF cells transiently transfectedwith ANO1 siRNA or treatedwith CFTR(inh)-172 (10 μM) (n = 8, p b 0.01). D) Representative and orig-
inal traces (left) and quantiﬁcation (right) of ANO1 Cl− efﬂuxmeasured in non-CF and CF cells under basal conditions (n = 55, p b 0.0001). E) Representative and original traces (left) and
quantiﬁcation (right) of ANO1 Cl− efﬂux measured in primary human non-CF and CF cells treated with the pharmacological ANO1 inhibitor (A01, 10 μM) (n = 5; p b 0.001).
2343M. Rufﬁn et al. / Biochimica et Biophysica Acta 1832 (2013) 2340–2351patients homozygous for the F508del mutation (37 ± 13 years) who
underwent lung transplantation. For non-CF patients, samples were ob-
tained in a non-pathologic area without inﬂammatory cells. After dis-
section of the tissue, samples were directly frozen in liquid nitrogen
before extraction.
2.2. Cell proliferation monitoring
Cell proliferationwas ﬁrst analyzed by counting. Non-CF and CF cells
were seeded and culturedwithin 48 h. Cells were dissociatedwith tryp-
sin–EDTA then counted using a hemocytometer.
Cell proliferation was also analyzed using real-time cell analysis
(RTCA). Cells were pelleted, re-suspended, and nucleo-transfected
(Lonza, Amboise, France) in transfection buffer in a concentration
of 106 cells/100 μL. After plating, cell growth was monitored every
30 min for 48 h using the xCELLigence RTCA MP instrument (Roche
Diagnostics, Meylan, France) as previously described [36]. The
impedance signal was analyzed by normalizing the data fromeach well for the ﬁrst value obtained after treatment initiation:
CInormalized = CItime x / CItime 0; the normalized impedance sig-
nal is designated “normalized cell index” hereafter.
2.3. Wound closure assay
Wound closure assays were performed using speciﬁc wound assay
chambers (Ibidi®, Biovalley, Marne la Vallée, France) that provided uni-
formwounds between twomonolayers. A constant number of cells pro-
ducing a conﬂuent layer within 72 h were seeded in each well of Ibidi®
silicone culture-inserts. The cells were incubated at 37 °C and 5% CO2.
After 24 h, cellswere treatedwith T16Ainh-A01 (Tocris Bioscience, Bris-
tol, United Kingdom), transfected with scrambled siRNA/ANO1 siRNA
(Life Technologies, Saint Aubin, France) or control vector/ANO1-GFP
vector (CliniSciences, Nanterre, France) (see below). The culture-
insert was removed 48 h later, leaving a cell-free gap (or wound) for
cell colonization. Wound closure was observed for 6 or 12 h under an
Axiovert 200 microscope (Zeiss). Mean migration rates during wound
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Fig. 4. Intracellular localization of ANO1 protein in bronchial epithelial cells. A) Immunocytochemical detection of endogenous ANO1 protein (green) in non-CF (top images) and CF (bot-
tom images) bronchial epithelial cell lines. Control: lack of ANO1 staining when the cells were exposed to secondary antibody only. Nuclei were stained with DAPI (blue). B) Immunocy-
tochemical detection of endogenous ANO1 protein (green) in primary non-CF (top images) and CF (bottom images) cells. Control: lack of ANO1 staining when the cells were exposed to
secondary antibody only. Nuclei were stained with DAPI (blue). The images are representative of more than six experiments. C) Intracellular localization of overexpressed ANO1 protein
(green) in non-CF (top images) and CF (bottom images) cell lines transfected with ANO1-GFP vector. Confocal immunoﬂuorescence images, magniﬁcation: ×630.Wheat germ agglutinin
(WGA)was used to stain the plasmamembrane (red). Merge of ANO1-GFP andWGA images (right). Nuclei were stainedwith DAPI (blue). The images are representative ofmore than six
experiments.
2344 M. Rufﬁn et al. / Biochimica et Biophysica Acta 1832 (2013) 2340–2351closure were assessed in three areas of the gap. At each time point and
in each area, ﬁve lengths were measured using AxioVision Rel software
(Zeiss).
2.4. ANO1 and CFTR inhibition
To induce transient ANO1 inhibition, we transfected non-CF
cell line using TransIT-TKO® transfection reagent (Euromedex,
Souffelweyersheim, France) with a set of three ANO1 siRNAs or with
scrambled siRNA, 24 to 48 h before the experiments.
A pharmacological inhibitor of ANO1 channel, T16Ainh-A01 (A01),
was used to inhibit ANO1 channel activity [37]. A01 stock solution
(10 mM) was made in dimethyl sulfoxide (DMSO). A01 was diluted toa ﬁnal concentration of 10 μM. Control experiments were performed
with DMSO at 1:1000 dilution.
CFTR activity was inhibited using CFTR(inh)-172 (Merck, Molsheim,
France) as previously described [38].
2.5. ANO1 immunocytochemistry
Cellswere cultured on glass coverslips andﬁxed in 4%paraformalde-
hyde in culture medium supplemented with 10% FBS for 15 min at
room temperature and then permeabilized with PBS containing 0.1%
Triton X-100 for 15 min. Cells were incubated with ANO1 primary anti-
body (Abcam, Paris, France) overnight in a humidiﬁed chamber at 4 °C.
For control experiments, the primary antibody was omitted. After being
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chial epithelial cells (n = 9; p b 0.0001), in lungs of wild-type (WT) and CF (F508del) mice (n = 9; p b 0.001) and in lung explants from non-CF and CF (F508del/F508del) patients
(n ≥ 7; p b 0.05) performed using RT-qPCR. GAPDH was used as a reporter gene. D) Western-blot showing ANO1 protein expression in non-CF and CF bronchial epithelial cells under
basal conditions (n = 6; p b 0.05). ANO1 expression was detected using anti-ANO1 antibody (top panel). Equal loading was veriﬁed using anti-β actin antibody (bottom
panel). E) Western-blot showing ANO1 expression in primary cultures of bronchial epithelial cells (MucilAir™) from non-CF (n = 5) and CF (n = 3) patients cultivated on
an air–liquid interface (p b 0.05).
2345M. Rufﬁn et al. / Biochimica et Biophysica Acta 1832 (2013) 2340–2351washed with PBS, cells were subsequently incubated with goat-anti-
rabbit IgGAlexa Fluor 488 (Life Technologies) secondary antibody
(1:2000 dilution) for 1 h at room temperature. After being washed
again in PBS, the coverslips were mounted using a Vectashield mount-
ing medium with DAPI (CliniSciences). For each cell model (cell lines
or primary cells) images were acquired using the same exposure time
with a 63× oil objective on an Axiovert 200 microscope (Zeiss). DAPI
and secondary antibody were visualized using 405 and 488 nm laser
lines, respectively.
2.6. ANO1 overexpression and ﬂuorescence detection
To induce ANO1 overexpression and monitor ANO1 localization, a
human GFP-tagged ANO1 vector was used (CliniSciences). The full-
length open reading frame (NM_018043) was subcloned into pCMV6-
AC-GFP vector with C-terminal GFP tag. GFP-tagged ANO1 vector was
transiently transfected into non-CF or CF cells using Lipofectin® trans-
fection reagent (Life Technologies) according to the manufacturer's
instructions.
The intracellular localization of the ANO1-GFP protein was deter-
mined using an Axiovert 200 microscope (Zeiss, Le Pecq, France). Live
cells were incubated with DAPI (10 μL/mL, 30 min) and Wheat Germ
Agglutinin (WGA) (5 μg/mL, 10 min) (Life Technologies) to label
respectively the nucleus and the plasma membrane. Images were
deconvoluted using Huygens software (Hilversum, Netherlands).2.7. Fluorescence assay of CFTR- and ANO1-dependent chloride channel
activities
CFTR and ANO1 Cl− activities were assessed by I− quenching of
halide-sensitive YFP-H148Q/I152L protein (Life Technologies). The
probewas transfected into the cells and, after 48 h of culturing, conduc-
tance was stimulated for CFTR and ANO1 respectively with cAMP ago-
nist cocktail and UTP (10 μM). I− solution (140 mM) was added, and
ﬂuorescence was recorded into a plate reader as previously described
[39]. The initial I− inﬂux rate following the addition of each solution
was computed from changes in YFP ﬂuorescence data using non-
linear regression and represents the original and representative traces.
For quantitative analysis, slope for ﬂuorescence quenching was
performed using a linear regression and correlates to the size of
the chloride conductance (I− uptake). The rate of change (ΔF/min)
is used for bar graph representation.
2.8. Total mRNA extraction and reverse transcriptase-polymerase chain
reaction (RT-PCR)
Total RNA extraction and reverse transcription were performed as
previously described [40]. Quantitative PCR was performed using an
ABI StepOnePlus™ (Life Technologies) and TaqMan technology. For rel-
ative quantiﬁcation, the ANO1mRNA level, calculated using the 2−ΔΔCt
method as published previously [41], was normalized for GAPDH and
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Fig. 6. Effect of ANO1 inhibition on proliferation and migration of non-CF bronchial epithelial cell line. A) Original traces of cell proliferation of non-CF cells transfected with scrambled
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(scr siRNA) (n = 6; p b 0.01). C) Representative photographs taken every 3 h during 6 h of wound closure of non-CF bronchial epithelial cell line transfected with scrambled siRNA (scr
siRNA) or ANO1 siRNA. D) Migration rate during repair of non-CF cells transfected with scrambled siRNA (scr siRNA) or ANO1 siRNA (n = 13; p b 0.001).
2346 M. Rufﬁn et al. / Biochimica et Biophysica Acta 1832 (2013) 2340–2351for the expression levels of respective non-CF models. Each sample was
assessed in triplicate to insure experiment quality.2.9. Total protein extraction and Western-blot analysis
As previously detailed [42], 20 μg of total proteins extractwas reduced
and size-separated on 8% SDS-polyacrylamide gels then transferred to
PVDF membranes (Bio-Rad, Marnes-la-Coquette, France), blocked in 5%
BSA (PAA, Les Mureaux, France) and incubated with speciﬁc primary an-
tibodies against ANO1 [43] (Abcam) and β-actin (Sigma, Saint Quentin
Fallavier, France). The proteins of interest were detected, imaged, and
quantiﬁed as previously described [40].2.10. Statistical analysis
All data are described as mean ± SD. In the ﬁgure legends, n indi-
cates the number of repeated experiments. Between-group differences
were tested using the unpaired Mann–Whitney test. Values of p lower
than 0.05 were considered signiﬁcant; in the ﬁgures, statisticallysigniﬁcant differences with p b 0.05 (*), p b 0.01 (**), and p b 0.001
(***) are indicated.3. Results
3.1. Proliferation and migration are delayed in CF bronchial epithelial cells
We ﬁrst compared proliferation of non-CF and CF bronchial epitheli-
al cell lines under basal conditions for 48 h using real time cell prolifer-
ation (Fig. 1A). After quantiﬁcation, we found signiﬁcantly lower
proliferation of the CF cells compared to the non-CF cells (Fig. 1B). Mea-
suringnon-CF and CF cell proliferation using aMalassez hemocytometer
produced similar results (data not shown).
We next evaluated cell migration by performing wound closure as-
says with non-CF and CF cell lines. Cell migration of non-CF and CF
cellswasﬁrst followed until full covering of the cell-free areas. Represen-
tative images of wound closure assays showed marked reduced migra-
tion rate in CF compared to non-CF cells (Fig. 1C). As illustrated in
Fig. 1D, the mean time needed to achieve full coverage of the cell-free
gap was signiﬁcantly increased in CF compared to non-CF cells (12 h
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wound closure assays within 6 h. Migration rate of CF cells (14.6 μm/h)
was signiﬁcantly lower than non-CF cells (61.9 μm/h) (n ≥ 5; p =
0.004). To be sure and to avoid any signiﬁcant cell proliferation, we
have also calculated cell migration rate during repair of non-CF and CF
cells during theﬁrst 2 h following the start of the experiment. The results
show that migration rate during this short period is signiﬁcantly
reduced, 2.3 fold lower (p b 0.05) in CF compared to non-CF cells
(p b 0.05; data not shown).
To conﬁrm these ﬁndings, we performed proliferation and wound
closure assays with primary bronchial epithelial cells from non-CF and
CF patients (Fig. 2). Fig. 2A and B showed that proliferation of CF cells
was signiﬁcantly reduced compared to non-CF cells. Migration rate dur-
ing repair was 2 fold lower in primary CF cells compared to non-CF cells
(Fig. 2C and D).
Taken together, these results indicated a delayed proliferation and a
reduced migration rate in CF compared to non-CF cells.3.2. ANO1 chloride channel activity is decreased in CF bronchial epithelial
cells
We then evaluated ANO1 Cl− activity in non-CF compared to CF
bronchial epithelial cells.
To ﬁrst characterize CFTR activity, we measured CFTR Cl− efﬂux
under basal conditions in both cell lines (Fig. 3A). CFTR Cl− activity
was assessed by I− quenching of a pre-transfected proteinwhich isﬂuo-
rescent andhalide-sensitive. Fluorescence quenching by I− inﬂux corre-
lates directly with the Cl− channel activity. CFTR was stimulated with a
cocktail of cAMP agonists prior to recording. As expected, YFP ﬂuores-
cence was signiﬁcantly greater in CF than in non-CF cells indicating
lower CFTR Cl− activity in CF cells. To ensure that we succeeded in sep-
arating CFTR and ANO1 Cl− efﬂux, we measured Cl− efﬂux stimulated
with either CFTR (Fig. 3B) or ANO1 (Fig. 3C) activators in non-CF cells
treated with CFTR or ANO1 inhibitors. CFTR Cl− efﬂux was signiﬁcantly
decreased by CFTR(inh)-172 but not by ANO1 siRNA and the opposite
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the speciﬁcity of our techniques.
We compared ANO1 Cl− activity under basal conditions in non-CF
and CF cells (Fig. 3D). YFP ﬂuorescence was signiﬁcantly less reduced
by purinergic stimulation in CF than in non-CF cells implying that
ANO1-dependent Cl− efﬂux was signiﬁcantly reduced in CF compared
to non-CF cell lines. Similar results were obtained on human primary
cells, and signiﬁcantly inhibited by a pharmacological inhibitor of
ANO1 (A01) (Fig. 3E).
3.3. Endogenous ANO1 protein is mainly localized at the plasmamembrane
of non-CF bronchial epithelial cells
We then hypothesized that the impairment in ANO1 Cl− activity in
CF cellsmight be ascribable to abnormal intracellular localization linked
to CF context.We investigated localization of endogenous ANO1protein
in bronchial epithelial cells. First, we performed immunocytochemistry
experiments on non-CF and CF cell lines using a speciﬁc ANO1 antibody.
Fig. 4A showed that ANO1 protein is localized at the plasma membrane
in non-CF cells but not exclusively because ANO1 was also detected in
the cytoplasm of these cells. Interestingly, we cannot detect ANO1 at
the plasma membrane in CF cells using the same exposure time. ANO1
appeared to be predominantly localized in the cytoplasm of CF cells.With primary non-CF and CF cells, ANO1 was detectable at the plasma
membrane in non-CF cells but not in CF cells conﬁrmingprevious results
(Fig. 4B).
To determine whether ANO1 trafﬁcking was normal in CF cells, we
induced ANO1 overexpression by transiently transfecting a GFP-tagged
ANO1 vector into non-CF and CF cell lines. The confocal immunoﬂuores-
cence images demonstrated that ANO1 protein co-localized with the
plasma membrane marker (WGA) (Fig. 4C) in both non-CF and CF
transfected cells. We observed, by halide sensor method, a 4.1-increase
of ANO1 activity when non-CF cells were transfected with this ANO1-
GFP plasmid (p b 0.001; data not shown). Thus, ANO1 trafﬁcking to the
plasma membrane was correct in CF bronchial epithelial cells.3.4. ANO1 protein expression is decreased in CF models
We then investigatedwhether the decreased ANO1Cl− activity in CF
cells might be due to a decreased ANO1 expression. We ﬁrst compared
ANO1mRNA expression under basal conditions using real-time quanti-
tative PCR (Fig. 5A). Interestingly,we founda strong signiﬁcant decrease
inANO1mRNAexpression in CF compared to non-CF cells.Western-blot
analysis showed that ANO1 protein expression was 3.5-fold lower in CF
cells compared to non-CF cells (Fig. 5D).
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models. We compared ANO1 mRNA expression in lungs from non-CF-
like and CF-like (homozygous for the F508del mutation) mice having
the same genetic background (Fig. 5B).ANO1 transcriptswere signiﬁcant-
ly decreased in lungs from CF-like mice. We also evaluated ANO1mRNA
expression in lung explants from non-CF and CF (F508del/F508del) pa-
tients, and found signiﬁcantly lower mRNA levels in the CF explants
(Fig. 5C). Finally, we measured ANO1 protein levels in primary bronchial
epithelial cells cultured in air–liquid interface obtained from non-CF and
CF (F508del/F508del) patients. ANO1 protein was signiﬁcantly reduced
in CF compared to non-CF human primary cells (Fig. 5E). Thus, ANO1 ex-
pression was decreased in all CF models carrying the homozygous
F508del mutation compared to corresponding non-CF models.
3.5. ANO1 is involved in delayed proliferation and migration of CF cells
To investigate the involvement of ANO1 in epithelial repair and to
test whether decreased in ANO1 activity and expression in CF models
might explain the difference in proliferation and migration rate, we
evaluated the consequences of ANO1 inhibition on cell proliferation
and migration. To decrease ANO1 expression in non-CF cell line, we
transfected either a speciﬁc ANO1 siRNA or scrambled siRNA. We
checked ANO1 siRNA efﬁciency by analyzing ANO1 mRNA and protein
levels after transfection. ANO1 mRNA levels were 2-fold decreased in
cells transfected with speciﬁc ANO1 siRNA (data not shown). We then
measured cell proliferation in these conditions. The normalized cell
index of non-CF cells transfected with ANO1 siRNA was signiﬁcantly
lower compared to control condition (Fig. 6A). Fig. 6B shows the areas
under the cell-proliferation curves. In addition, wound closure assays
showed that the migration rate during repair was signiﬁcantly de-
creased in non-CF cells transfected with ANO1 siRNA compared to
cells transfected with scrambled siRNA (Fig. 6C and D).
To determinewhether the channel activity of ANO1was required for
cell proliferation andmigration, we performed proliferation andwound
closure assaywith primary non-CF cells treated or notwith a pharmaco-
logical blocker of ANO1 channel i.e., T16Ainh-A01 or A01. Fig. 7A and B
show that primary non-CF cell proliferation was signiﬁcantly decreased
in the presence of A01. Wound closure assay with previously described
conditions showed that A01 induced a signiﬁcantly marked decrease in
cell migration (Fig. 7C and D).
Finally, to determine whether ANO1 overexpression may improve
CF cell proliferation and epithelial repair, we analyzed the consequences
of ANO1 overexpression on proliferation and migration rate of the CF
cell line. We transfected ANO1-overexpression or control vector in CF
cells and checked transfection efﬁciency by comparing ANO1mRNA ex-
pression in CF cells transfected with ANO1 overexpression vector or
control vector. As expected, ANO1mRNA levels were 70-fold increased
with ANO1-overexpression vector (data not shown). We measured
also ANO1 Cl− activity in cells transfected with ANO1 overexpression
vector and showed that ANO1 overexpression increased ANO1 Cl− ef-
ﬂux (data not shown).
Real time proliferation experiments showed that proliferation was
signiﬁcantly increased in CF cells overexpressing ANO1 compared to
control (Fig. 8A and B). Although the migration defect was not
completely corrected, themigration rate of CF cells was signiﬁcantly in-
creased by ANO1 overexpression (Fig. 8C and D).
Thus, these data established that ANO1 is involved in cell prolifera-
tion and in the abnormal repair observed in CF bronchial epithelial cell
monolayers and that ANO1 overexpression improves these two param-
eters in CF cells.
4. Discussion
Although the existence of chloride channels other than CFTR was
known for more than 30 years [6], their possible contribution to the
progression of CF pathology remains unclear. Here, after conﬁrmingthat CF bronchial epithelial cells displayed an abnormal repair process,
we report the ﬁrst evidence that ANO1 expression is signiﬁcantly de-
creased in various models of CF bronchial epithelia homozygous for
the F508del mutation compared to non-CF models. The decrease in
ANO1 expression resulted in decreased ANO1 Cl− secretion by CF bron-
chial epithelial cells. We also show that ANO1 is involved in cell prolif-
eration and migration and that ANO1 overexpression in CF cells leads
to improve bronchial epithelial repair. All together, our data support a
role for defective ANO1 expression and activity in the delayed repair
of CF airway epithelium.
We ﬁnd decreased ANO1 Cl− activity in CF compared to non-CF
bronchial epithelial cells. Several groups have assayed ANO1 activity
in non-CF cells, but none compared CF and non-CF models. However,
before the molecular identiﬁcation of ANO1 as a CaCC candidate, global
CaCC currents were described as normal or increased in nasal epithelial
cells from CF patients [8–11]. Several hypotheses may explain the dis-
crepancies between these ﬁndings and our results. First, ANO1 may be
only a minor component of Ca2+-activated Cl− conductance [37], al-
though this is still debated [44]. The ANO1-speciﬁc Cl− efﬂux measured
in our study may not represent global Ca2+-activated Cl− conductance
recorded in previous studies. Other unidentiﬁed molecular CaCCs
expressed in the airway could be up-regulated in CF thereby increasing
the total Ca2+-activated Cl− conductance. Second, supporting our
results, a more recent study showed signiﬁcantly decreased ATP-
induced Cl− currents in cultures of bronchial and bronchiolar epithelial
cells from CF compared to non-CF patients [45]. Most studies comparing
global CaCC activity between non-CF and CF models were done using
only nasal epithelium cells and not bronchial cells. We propose that
CaCC distribution and regulation may differ between the upper and
lower airways. This hypothesis is supported by a study reporting con-
siderable differences in global gene expression patterns between the
nasal and the bronchial CF epithelium [46], suggesting that the nasal ep-
ithelium may be a poor surrogate for the lower airway epithelium.
Our data indicate that the decreased Cl− channel activity in CF cells
is ascribable to decreased ANO1 mRNA and protein expression. To our
knowledge, a single previous study showed also signiﬁcantly decreased
ANO1 mRNA levels in CF compared to non-CF bronchial epithelial cells
[47], which the authors ascribed to clonal drift. In our work, the conﬁr-
mation that ANO1 mRNA and protein levels are low in other relevant
and non-immortalized CF models suggests instead true down-
regulation of ANO1 expression in CF that may participate to the
worsening of the disease. Ourﬁrst hypothesis to explain such decreased
expression involves the unfolded protein response (UPR). This cell re-
covery mechanism was described as activated in CF airways notably
by the presence of F508del CFTR to regulate protein load of the endo-
plasmic reticulum [48]. Activation of the UPR induces transcriptional
regulations and for example a decreased CFTR mRNA expression [49].
ANO1 decreased expression in CF bronchial epithelial models may be
related to this mechanism. This hypothesis may be linked to the results
of Kunzelmann and collaborators [26]. These authors show that cur-
rents generated by ANO1 are inhibited by CFTR suggesting a link be-
tween both proteins. Moreover, a previous study documented that a
marked decrease in ANO1 mRNA expression in sino-nasal epithelium
by hypoxia exposure may be through a decrease in steady-state
mRNA [50]. These data suggest a role for oxygen restriction, present in
advanced CF lung disease, which could explain the decreased ANO1 ex-
pression in CF human lung explants in our study. The exactmechanisms
responsible for the decreases in ANO1 mRNA and protein in CF lower
airways remain to be identiﬁed.
The secondmajor ﬁnding fromourwork is the involvement of ANO1
in the abnormal proliferation and repair of CF bronchial epithelial cells.
Our study ﬁrst conﬁrms that CF bronchial epithelial cells show less pro-
liferative potential and decreasedmigration rate during epithelial repair
compared to non-CF cells. Indeed, similarly, marked delays in wound
closure have been documented in another pair of CF and non-CF bron-
chial epithelial cell lines and also in CF versus non-CF human primary
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defect of the CF airway epithelia due to CFTRmutation [5], effects of bac-
terial infections [52] and effects of the chronic inﬂammatory context
seen in CF airways [2]. The mechanisms that underlie wound repair re-
semble those involved in tumor cell migration: in both cases, ion chan-
nels regulating cell volume and membrane potential play a crucial role
[53]. In the present study,we demonstrate that speciﬁc ANO1 inhibition
in non-CF cells induces a decrease of cell proliferation and migration
during repair. These results corroborate cancer studies indicating in-
volvement in cell proliferation of Cl− channels in general and of ANO1
in particular [30,31,54]. In an earlier study, it has been shown that loss
of CFTR Cl− activity directly impaired wound closure by decreasing
the lamellipodium surface area, thereby impairing cell migration [55].
Conceivably, the diminished ANO1 Cl− activity observed in CF bronchial
epithelial cells may have a similar effect on lamellipodia.
In conclusion, our study highlights for the ﬁrst time a default of both
ANO1 activity and expression in CF airways and supports a major role
for ANO1 deﬁciency in abnormal epithelial repair observed in CF air-
ways. These ﬁndings indicate the potential interest to develop drugs
targeting this protein to prevent the progression of lung disease in cystic
ﬁbrosis patients.
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